Pfizer Inc. (NYSE:PFE) Shares Purchased by Costello Asset Management INC

Costello Asset Management INC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 461.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,925 shares of the biopharmaceutical company's stock after purchasing an additional 46,795 shares during the period. Costello Asset Management INC's holdings in Pfizer were worth $1,647,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Olistico Wealth LLC acquired a new stake in Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the 2nd quarter valued at $29,000. Quarry LP purchased a new stake in Pfizer in the 2nd quarter worth $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter worth $34,000. Finally, ESL Trust Services LLC purchased a new position in Pfizer during the first quarter valued at $37,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Trading Down 1.2 %

Pfizer stock traded down $0.32 during midday trading on Friday, hitting $26.72. 55,951,315 shares of the stock were exchanged, compared to its average volume of 38,136,520. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $151.42 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 0.85 and a beta of 0.67. The stock's 50-day simple moving average is $28.89 and its 200 day simple moving average is $28.65. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.17) EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's payout ratio is 227.03%.

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 31st. Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They set a "neutral" rating and a $30.00 target price for the company. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Daiwa America upgraded Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.